What Is a Stomach Biopsy, How Is It Performed and How Are Results Interpreted?
In this article
What is a stomach biopsy, how is it performed and how are results interpreted?
A stomach biopsyinvolves taking small tissue samples from the stomach lining during endoscopy and examining them microscopically in a pathology laboratory. Gastritis, ulcers, Helicobacter pylori (H. pylori) infection, precancerous changes such as atrophy and intestinal metaplasia, and stomach cancer can be diagnosed this way. When cancer is diagnosed, the same samples undergo biomarker testing to guide treatment. This article explains why and how biopsies are performed, preparation, risks and, most importantly, how to read the pathology report in light of current guidelines.
- How is it performed? During upper endoscopy (esophagogastroduodenoscopy), with small forceps passed through the endoscope, usually under sedation, in 5-20 minutes. Tissue sampling is painless.
- How many samples? For gastritis and H. pylori, guidelines recommend at least 2+2 samples from the stomach body and outlet in separate containers (often 5 samples); when cancer is suspected, at least 5, preferably 6-8 samples are recommended.
- Preparation: Generally 6-8 hours of fasting; aspirin and most blood thinners are not stopped for low-risk biopsy, but discuss every drug with your doctor. For H. pylori testing, stop acid-suppressing PPIs 2 weeks and antibiotics 4 weeks beforehand.
- Risk: Very low. Perforation in diagnostic endoscopy occurs once per 2.500-11.000 procedures; the most common problems involve sedation.
- Results: Most biopsies are reported within a few days to 1 week; additional stains, culture and molecular tests take longer.
- After the report: If H. pylori is positive, it is treated; extensive atrophy or metaplasia warrants endoscopic surveillance every 3 years; dysplasia and cancer require further evaluation.
- Biopsy and follow-up recommendations from Europe’s 2025 MAPS III guideline were added.
- Rules for blood thinners, fasting and stopping medications before H. pylori testing were revised according to current guidelines.
- An explanatory table of pathology report terms, a “what happens after the report?” diagram and H. pylori antibiotic resistance data from Turkey were added.
- HER2, PD-L1, MSI and Claudin 18.2 tests performed on stomach cancer biopsies were added.
Stomach cancer is an important health problem in Turkey. According to the International Agency for Research on Cancer’s 2024 estimates, approximately 12.900 new stomach cancer diagnoses occur annually in our country; it is the 7th most common cancer but ranks 3rdin cancer deaths. This difference indicates that it is often detected at an advanced stage. We explain symptoms and diagnosis in our stomach cancer guide .
We discuss what biopsy means in general and its types in our article what is a biopsy . This article focuses specifically on stomach biopsy.
Why is a stomach biopsy performed?
Your doctor may request endoscopy and stomach biopsy in the following situations:
- Warning (alarm) symptoms: Black, tarry stool or vomiting blood, unintentional weight loss, difficulty swallowing, persistent vomiting, iron-deficiency anemia.
- Persistent complaints: Stomach pain, indigestion, nausea, loss of appetite or early satiety despite treatment.
- Investigating H. pylori: Especially if endoscopy is already being performed; biopsy also allows antibiotic resistance testing.
- A finding on endoscopy: An ulcer, polyp, mass, or color or surface change.
- Monitoring precancerous changes: People diagnosed with atrophic gastritis, intestinal metaplasia or dysplasia.
- High risk: A family history of stomach cancer or certain hereditary syndromes.
- After a cancer diagnosis: Testing biomarkers that determine treatment.
For stomach ulcers, biopsy to exclude cancer and confirmation of healing by follow-up endoscopy are common practice. Unexplained iron deficiency should prompt consideration of hidden gastrointestinal bleeding and should not simply be dismissed with iron medication .
How is a stomach biopsy performed?
A stomach biopsy is taken during upper endoscopy . A finger-thick flexible tube with a light and camera at its tip (endoscope) passes through the mouth into the esophagus, stomach and beginning of the duodenum. Because these are examined together, the medical name is esophagogastroduodenoscopy. Examination of the large intestine is called colonoscopy (lower endoscopy).
The doctor introduces a little air or carbon dioxide for a better view and carefully examines the stomach wall. Small forceps passed through the endoscope take rice-grain-sized tissue samples. Sampling is painless because the stomach lining has very few pain-sensitive nerve endings. Most procedures today are performed under sedation with intravenous medication to relax the patient; those declining sedation can receive a local anesthetic throat spray. The procedure generally takes 5-20 minutes.
How many biopsies are taken, and from where?
Sampling sites and numbers directly affect reliability. For gastritis, H. pylori and precancerous changes, the Updated Sydney Systemrecommends 5 gastric biopsies. Europe’s 2025 MAPS III guideline recommends at least 2 samples from the antrum/incisura and 2 from the body, sent in two separately labeled containers; an extra incisura biopsy is optional. Any visible lesion is biopsied separately.
Figure 1 · Biopsy map for gastritis and H. pylori
Biopsies from different regions in separate containers show the extent of changes.
More samples are needed if stomach cancer is suspected. The College of American Pathologists (CAP) recommends, if possible, for stomach cancer HER2 testing, at least 5, ideally 6-8 biopsies . Because different regions of the same stomach tumor may have different characteristics, too few samples can mislead both diagnosis and biomarker testing. We explain the endoscopic appearance of stomach cancer in this article .
Preparation before the procedure
| Topic | Current recommendation |
|---|---|
| Fasting | For sedated procedures, international anesthesia guidelines require at least 6 hours after a light meal and 2 hours after clear liquids such as water. Most centers generally request 6-8 hours of fasting; follow your center’s instructions. |
| Antiplatelet drugs such as aspirin and clopidogrel | British and European gastroenterology societies (2021) recommend that, for low-risk endoscopic procedures such as biopsy, these drugs be continued . |
| Warfarin (Coumadin) | Usually continued for low-risk procedures; during the preceding week, ensure INR is not above the target range. |
| New-generation blood thinners (rivaroxaban, apixaban, dabigatran, edoxaban) | For low-risk procedures, skipping the morning dose on the procedure day is recommended. |
| If testing for H. pylori | Acid-suppressing medications (PPIs: omeprazole, pantoprazole, lansoprazole, esomeprazole, etc.) should be stopped 2 weeks, and antibiotics and bismuth 4 weeks beforehand; otherwise results may be false negative. |
| Other | Dentures are removed. Discuss how to use diabetes medications on the fasting day. Bring an accompanying person because you must not drive that day after sedation. |
Your blood thinners: do not stop or change them on your own. In patients with heart stents, valves or a history of clots, unnecessarily stopping medication may be far more dangerous than bleeding risk. Always tell the endoscopy team who prescribed the medication and why you take it.
After the procedure and risks
You remain under observation briefly until sedation wears off, and most patients go home that day. Introduced air may cause bloating and gas, and there may be mild throat burning or pain, generally resolving within hours. Unless instructed otherwise, eating and drinking can resume once the swallowing reflex has fully recovered.
Diagnostic upper endoscopy is very safe. According to an American Society for Gastrointestinal Endoscopy (ASGE) review:
- All complications are reported between once per 200 and 10.000 procedures.
- Approximately %60 of complications involve the heart, lungs and sedation.
- Perforation Once per 2.500 to 11.000 procedures.
- Clinically significant bleeding is rare; a small amount of oozing at the biopsy site is normal.
If severe or worsening abdominal or chest pain, fever, vomiting blood, black stool, shortness of breath or difficulty swallowing occurs afterward, promptly contact the procedure center or emergency department.
When are results available?
Biopsy samples are chemically fixed, embedded in paraffin, cut into thin sections, stained and examined by a pathologist. Under Royal College of Pathologists performance targets, the great majority of diagnostic biopsies should be reported within 7 days . Special H. pylori stains, immunohistochemistry, molecular tests (such as antibiotic resistance), culture or cancer biomarkers may take longer. Ask your center for the exact timing.
How to read the pathology report?
A stomach biopsy report is often among the hardest documents for patients to understand. The table below summarizes common terms and their general importance. Some are explained in more detail in our article on pathology report terminology .
| Term in the report | Meaning | Importance |
|---|---|---|
| Chronic gastritis (inactive) | Long-standing mild inflammation of the stomach lining | usually harmless |
| Chronic active gastritis | Ongoing inflammation, usually with H. pylori | treatment needed |
| H. pylori positive | Stomach bacterium seen | should be treated |
| Atrophy (atrophic gastritis) | Loss of gastric glands; a result of prolonged inflammation | follow-up depends on extent |
| Intestinal metaplasia (complete / incomplete) | Replacement of stomach cells by intestinal-type cells; incomplete type carries higher risk | follow-up depends on extent |
| OLGA / OLGIM stage (0-IV) | Staging showing the extent and severity of gastric atrophy or metaplasia | III-IV: high risk |
| Dysplasia (low / high grade) or intraepithelial neoplasia | Precancerous cell changes | further evaluation needed |
| Adenocarcinoma | The most common stomach cancer type (%90-95) | cancer |
| Signet-ring cell / poorly cohesive carcinoma | Diffuse-type adenocarcinoma with scattered spreading cells | cancer |
| Neuroendocrine tumor (formerly carcinoid) | Tumor developing from hormone-producing cells | depends on type |
| MALT lymphoma | Lymphoma developing from gastric lymphoid tissue; associated with H. pylori | often regresses with H. pylori treatment in early cases |
| GIST | Tumor developing from deeper stomach wall layers | usually diagnosed by endoscopic ultrasound rather than superficial biopsy |
Two classifications commonly appear in gastric cancer pathology reports: the World Health Organization classification (tubular, papillary, mucinous, poorly cohesive/signet-ring cell, mixed) and the Lauren classification (intestinal, diffuse, mixed). Intestinal type generally develops through the steps shown below; diffuse type may not follow them and may be associated with hereditary causes.
Figure 2 · The path from gastritis to cancer and the role of H. pylori treatment
Intestinal-type gastric cancer generally develops through stages over years. Every stage offers an opportunity to intervene.
What happens after the report?
Europe’s MAPS II (2019) and MAPS III (2025) guidelines define who needs follow-up endoscopy and how often for precancerous changes:
Figure 3 · Next step according to the report finding
Simplified summary of European MAPS II and MAPS III recommendations.
We discuss what intestinal metaplasia means in our intestinal metaplasia article, and stomach cancer prevention and high-risk groups in this article .
H. pylori testing and antibiotic resistance through biopsy
Stomach biopsy offers several ways to detect H. pylori:
- Rapid urease test: A biopsy sample is placed in a special gel; it changes color if bacteria are present. Results take minutes to hours.
- Histology: The pathologist sees bacteria microscopically while assessing gastritis severity, atrophy and metaplasia.
- Culture and antibiotic susceptibility testing: Bacteria are grown in the laboratory to determine which antibiotics they resist.
- Molecular (PCR) test: Directly demonstrates bacterial presence and mutations causing clarithromycin resistance. Under Maastricht VI, samples taken for rapid urease testing can also be used for PCR.
Published in 2022, the Maastricht VI/Florence consensus recommends routine susceptibility testing (culture or PCR), even before first treatment where possible, because antibiotic resistance is increasing worldwide. It notes that the %15 resistance threshold previously accepted for empirical clarithromycin treatment has now been exceeded in most regions.
Turkey is an important example: a meta-analysis covering 2005-2020 and combining 20 Turkish studies found H. pylori resistance to clarithromycin at %26,7, metronidazole at %28,4 and levofloxacin at %19,6; resistance to amoxicillin (%1,3) and tetracycline (%0,7) was very low. First-line success of clarithromycin- or levofloxacin-based regimens may therefore be limited in our country. We explain H. pylori treatment’s role in preventing stomach cancer in this article .
Tests performed on biopsy when stomach cancer is diagnosed
When cancer is found, the same tissue is tested to show which drugs will work. The main biomarkers assessed today in advanced gastric and gastroesophageal junction cancer are:
| Biomarker | How is it tested? | Importance for treatment |
|---|---|---|
| HER2 | First immunohistochemistry (IHC); if 2+, additional ISH testing | If positive, HER2-targeted therapies such as trastuzumab are added |
| PD-L1 (CPS score) | Immunohistochemistry | Shows who is more likely to benefit from adding immunotherapy to chemotherapy |
| MMR / MSI | Immunohistochemistry or molecular testing | MSI-high tumors respond well to immunotherapy; also relevant to hereditary Lynch syndrome |
| Claudin 18.2 | Immunohistochemistry; moderate-to-strong staining in at least %75 of tumor cells is positive | For positive, HER2-negative tumors, zolbetuximab (FDA, 18 October 2024); approximately %38 screened are positive |
| FGFR2b | Immunohistochemistry | Investigational: in the bemarituzumab study (FORTITUDE-101), survival benefit diminished with longer follow-up; the immunotherapy combination study was stopped in 2025 |
Reliable tests require adequate numbers and quality of biopsies, so 6-8 samples are recommended when cancer is suspected. We discuss zolbetuximab’s status in our country in our Vyloy article, the HER2 concept in what is HER2 , and more extensive genetic testing in next-generation sequencing . We discuss the importance of a second pathology opinion in cancer diagnosis in this article .
- “Chronic gastritis” is not cancer. This very common finding, present in most reports, is often insignificant. What matters is whether active inflammation, H. pylori, atrophy, metaplasia or dysplasia is present.
- Intestinal metaplasia is not “the beginning of cancer.” It increases risk, but usually does not progress to cancer. Follow-up depends on extent and risk factors.
- One normal biopsy does not exclude everything. Too few biopsies or incorrect sampling sites can miss changes; persistent symptoms may require reassessment.
- H. pylori testing while taking acid suppressants can mislead. Failure to stop PPIs 2 weeks beforehand is among the commonest causes of false negatives.
- H. pylori treatment success must be confirmed. Because antibiotic resistance is high in Turkey, treatment is not always successful.
The situation in Turkey
- Stomach cancer: According to IARC’s 2024 estimates, approximately 12.900 new diagnoses and 9.200 cancer deaths annually; the 5th most common cancer in men. We shared our assessment of stomach cancer’s future in our country in this article .
- H. pylori prevalence: In the TURHEP study conducted in 2003-2004 in 55 provinces, among adults, %82,5. More recent single-center studies report approximately %40-60; authors note an overall decline from above %80 to approximately %50-60.
- Antibiotic resistance: Clarithromycin resistance approximately %27, metronidazole %28, levofloxacin %20 (meta-analysis of Turkish studies from 2005-2020).
- Screening: Turkey has no national endoscopic stomach cancer screening program; endoscopy is performed according to symptoms and risk.
Frequently asked questions
- Does a stomach biopsy hurt?
- No. The stomach lining has very few pain-sensitive nerve endings, so tissue removal is not felt. The procedure is usually sedated; mild bloating and throat burning may follow.
- Does a stomach biopsy spread cancer?
- No. There is no evidence that biopsy spreads cancer. On the contrary, it is essential for correct diagnosis and treatment.
- A biopsy was taken; is cancer suspected?
- Not always. Most stomach biopsies are taken for gastritis, H. pylori or routine assessment. Doctors can biopsy a normal-looking stomach for H. pylori and metaplasia.
- My report says “chronic active gastritis, H. pylori (+).” What should I do?
- This indicates ongoing bacterial inflammation. Your doctor will plan eradication treatment. Success should be checked at least 4 weeks after completion by breath or stool testing, with acid suppressants stopped 2 weeks beforehand.
- Intestinal metaplasia was found. Will I get cancer?
- Most likely not. It increases risk, but usually does not progress to cancer. Your doctor decides on surveillance based on extent, type and family history; extensive cases warrant endoscopy every 3 years.
- My result is normal but symptoms continue. What next?
- A normal biopsy largely indicates no serious disease. Symptoms may be due to reflux, functional dyspepsia, gallbladder disease or other causes; your doctor may request further tests.
- Should I stop my blood thinner?
- Usually not. Current guidelines continue aspirin and clopidogrel for low-risk procedures such as biopsy, generally continue warfarin, and omit only the procedure-morning dose of new-generation blood thinners. Always make this decision with the endoscopy team and prescribing doctor.
Glossary
- Upper endoscopy (esophagogastroduodenoscopy)
- Examination of the esophagus, stomach and duodenum with a flexible camera-equipped tube.
- Gastritis
- Inflammation of the stomach lining.
- Atrophy
- Reduction or loss of gastric glands.
- Intestinal metaplasia
- Replacement of stomach lining cells by intestinal-type cells.
- Dysplasia
- Precancerous cell changes, classified as low or high grade.
- OLGA / OLGIM
- Staging systems classifying stomach cancer risk by extent of atrophy (OLGA) or intestinal metaplasia (OLGIM).
- Eradication
- Complete elimination of H. pylori with medication.
- Sedation
- Relaxation and sleepiness during the procedure induced by intravenous medication.
- Biomarker
- A measurable feature showing which treatment a tumor will respond to (such as HER2, PD-L1, Claudin 18.2).
DROZDOGAN Academy Commentary
Stomach biopsy is among gastroenterology’s commonest procedures. Its value extends beyond finding cancer: accurately identifying H. pylori and precancerous changes is one of the most effective ways to prevent stomach cancer.
⚡ Why it matters
Turkey has high H. pylori prevalence and antibiotic resistance, and stomach cancer is often detected late. Adequate biopsies from correct sites and a correctly interpreted report determine personal risk and surveillance needs.
✅ Strengths
A safe, brief, usually outpatient procedure. Diagnosis, H. pylori testing, antibiotic resistance and cancer biomarkers can be assessed in the same session. European guidelines increasingly clarify who needs surveillance.
⚠️ Limitations
Changes may be missed when sampling sites and numbers do not follow standard protocols. Report terminology can confuse and worry patients. Turkey lacks national gastric cancer screening and widespread antibiotic susceptibility testing.
🩺 What to do in practice
- Before endoscopy, report your acid suppressants, antibiotics and blood thinners to the team.
- Always review your report with your doctor; particularly ask about the extent of atrophy, metaplasia and dysplasia .
- If treated for H. pylori, do not skip confirmation of success .
- Before endoscopy, if stomach cancer runs in your family, be sure to mention it.
- When cancer is diagnosed, ensure HER2, PD-L1, MSI and Claudin 18.2 tests are performed.
❓ Open questions
What is Turkey’s most effective first-line H. pylori treatment? Should susceptibility testing become routine? Should targeted endoscopic screening be established in high-risk regions and families? How much will AI-assisted endoscopy improve early lesion detection?
Our brief verdict: Stomach biopsy is safe, quick and highly informative. What matters is correct preparation, especially stopping acid suppressants; standard sampling numbers and sites; and interpretation with an experienced physician. “Chronic gastritis” and “intestinal metaplasia” are usually opportunities for appropriate follow-up rather than panic.
- This is the September 2026 update of our stomach biopsy article. It was prepared from public sources: European Society of Gastrointestinal Endoscopy MAPS II and MAPS III guidelines, Maastricht VI consensus, British and European gastroenterology antithrombotic guidelines, American Society of Anesthesiologists fasting guidelines, ASGE review, College of American Pathologists, FDA, IARC and published Turkish studies.
- Corrections from the previous version: Current fasting intervals replaced “12 hours of fasting”; current antithrombotic recommendations replaced “blood thinners may be stopped”; “all biopsies are sedated” was softened; sourced turnaround information was added; “neuroendocrine tumor” replaced “carcinoid”; and biopsy numbers, surveillance, H. pylori tests, resistance and biomarkers were added. The old “these are absent in a normal result” list became an explanatory terminology table.
- Information from secondary sources: The Updated Sydney System’s 2-1-2 distribution came from a guideline summary; IARC data and Turkey’s antibiotic resistance meta-analysis came from summary pages.
- Unverified points: Exact timing of follow-up endoscopy for gastric ulcers; current Turkish Gastroenterology Association H. pylori recommendations; current nationwide H. pylori prevalence; bemarituzumab’s regulatory status as of 2026.
- Based on general knowledge: Low pain perception in the stomach lining, procedural details, progression from gastritis to cancer (Correa model), hereditary links of diffuse cancer and GIST diagnosis are presented as established medical knowledge.
- The terminology table’s “importance” column, “Our assessment” and Academy commentary are our own.
- Diagrams derive from verified statements in the text and contain no new data.
- This article is not personal medical advice. Consult your doctor about preparation and interpreting your report.
Sources
- Pimentel-Nunes P et al. Management of epithelial precancerous conditions and lesions in the stomach (MAPS II). Endoscopy. 2019;51:365-388.
- ESGE, EHMSG, ESP. Management of epithelial precancerous conditions and early neoplasia of the stomach (MAPS III). Endoscopy. 2025.
- Malfertheiner P et al. Management of Helicobacter pylori infection: the Maastricht VI/Florence consensus report. Gut. 2022;71(9):1724.
- Veitch AM et al. Endoscopy in patients on antiplatelet or anticoagulant therapy: BSG and ESGE guideline update. Gut. 2021;70(9):1611.
- American Society of Anesthesiologists. Practice guidelines for preoperative fasting. Anesthesiology. 2017;126(3):376.
- ASGE Standards of Practice Committee. Adverse events of upper GI endoscopy. Gastrointest Endosc. 2012;76(4).
- Shah SC et al. AGA clinical practice update on the diagnosis and management of atrophic gastritis. 2021 (Emory and Endoscopy Campus summaries).
- College of American Pathologists. HER2 testing in gastroesophageal adenocarcinoma: guideline FAQs (Bartley AN et al., 2016).
- The Royal College of Pathologists. Key performance indicators in pathology. 2013.
- PathologyOutlines. Stomach: carcinoma – general (2025); stomach dysplasia.
- National Cancer Institute. Gastric cancer treatment (PDQ), 2025.
- FDA. FDA approves zolbetuximab-clzb with chemotherapy for gastric or gastroesophageal junction adenocarcinoma. 18 October 2024. Astellas press release, 21 October 2024.
- The ASCO Post. FORTITUDE-101: bemarituzumab plus chemotherapy (ESMO 2025). December 2025. Fierce Biotech: discontinuation of FORTITUDE-102, November 2025.
- International Agency for Research on Cancer. Türkiye fact sheet, GLOBOCAN 2024 estimates. July 2026.
- Özaydın N et al. Prevalence and risk factors of Helicobacter pylori in Turkey (TURHEP). BMC Public Health. 2013;13:1215.
- Özden and Bulur. Turk J Gastroenterol. January 2026.
- Ayaş and Gürol. H. pylori antibiotic resistance in Turkey: meta-analysis. Microb Drug Resist. 2023;29(3).
- Gökçekuyu et al. Unacceptable antibiotic resistance rates in Helicobacter pylori. Turk J Gastroenterol. 2021;32(3):269-275.
Was this article helpful?
Your feedback helps us improve our content.
Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.